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MAOI   Monoamine oxidase inhibitors 
MDD   Major depressive disorder 
MDE   Major depressive episode 
NA   Noradrenaline or norepinephrine 
NMS   Neuroleptic Malignant Syndrome 
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SUMMARY 
Ana Stručić 
Analysis of indications for electroconvulsive therapy in the hospitalized psychiatric 
patients 
 
 
All around the world guidelines and indications for electroconvulsive therapy (ECT) differ. 
However, ECT is considered the most effective in treating depression, schizophrenia, mania, 
suicidality, and treatment resistance. The goal of this research was to analyze ECT indications 
from medical history of the hospitalized patients in the time period 2010-2017. There were 
213 patients treated with ECT, previously diagnosed with schizophrenia, depression or bipolar 
disorder. The leading ECT indication was treatment resistance associated with already 
mentioned diagnoses, followed by suicidality, catatonia and neuroleptic malignant syndrome. 
Men were significantly younger than women receiving the first ECT treatment and more often 
they had resistant positive schizophrenia symptoms. Women more often had negative resistant 
schizophrenic symptoms and mood disorders as an indication. Within one year after receiving 
ECT, 1/3 of the patients were rehospitalized without differences in indications. Therapy 
resistance is gaining more importance as an ECT indication. Further studies will provide a 
better insight into ECT as a treating method, better understanding of the treatment, targeted 
and timely set indications as well as neutralization of controversies around ECT. 
 
Keywords:  ECT, indications for ECT, pharmacotherapy resistance, psychosis, suicidality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SAŽETAK 
Ana Stručić 
Analiza indikacija za elektrokonvulzivnu terapiju u hospitaliziranih psihijatrijskih 
bolesnika 
 
 
Diljem svijeta smjernice i indikacije za elektrokonvulzivnu terapiju (EKT) variraju, a EKT se 
smatra učinkovitim u liječenju depresije, shizofrenije, manije, suicidalnosti i terapijske 
rezistencije. Cilj ovog istraživanja bio je analizirati indikacije za EKT u hospitaliziranih 
bolesnika u periodu od 2010. do 2017. godine iz medicinske dokumentacije. Liječenje EKT-
om primilo je 213 bolesnika s dijagnozom shizofrenije, depresije ili bipolarnog poremećaja. 
Vodeća indikacija za aplikaciju EKT-a bila je terapijska rezistencija povezana s navedenim 
dijagnozama, a rjeđe suicidalnost, katatonija i maligni neuroleptički sindrom. Muškarci su bili 
značajno mlađi od žena prilikom prve aplikacije EKT-a, i češće su imali indikaciju 
rezistentnih pozitivnih simptoma shizofrenije. Bolesnice su češće imale indikaciju rezistentne 
negativne shizofrenije i poremećaja raspoloženja. Unutar godine dana nakon EKT-a, ponovo 
je hospitalizirana trećina bolesnika, bez razlika između indikacija. Terapijska rezistencija 
dobiva sve veći značaj kao indikacija za liječenje EKT-om, uz tradicionalne primarne 
indikacije. Istraživanja primjene EKT-a u liječenju psihičkih bolesti omogućit će bolje 
razumijevanje ove metode liječenja, ciljano i pravovremeno postavljanje indikacija, te 
smanjivanje kontroverzi povezanih s ovom metodom liječenja. 
 
Ključne riječi: EKT, indikacije za EKT, rezistencija na psihofarmake, psihoza, suicidalnost
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INTRODUCTION 
Electroconvulsive therapy (ECT) is a method of treatment that cannot dispose of the negative 
connotation thanks to the controversial past, the spread of disinformation and the ignorance 
that is still present to this day among the nonprofessionals, as well as among the professionals. 
In order to create a gap between past and present, and to get the term ECT destigmatized, 
some new terms are introduced: electrostimulative therapy (EST) or electroneuromodulative 
therapy (ENMT) (1).  
At the time the ECT was discovered, it was believed that epileptic seizures prevent 
schizophrenia and that people who had suffered from seizures were in some way protected 
against schizophrenia. In 1933, while the young Hungarian psychiatrist and neuropathologist 
Lasislas von Meduna worked at the Budapest Psychiatric Investigation Institute, he noticed 
antagonistic activity between these two diagnoses – psychotic patients had fewer epileptic 
seizures, and patients with diagnosed epilepsy had fewer psychoses (2). Based on this, he 
concluded that an artificially induced epileptic attack could have a preventive effect, namely 
treat schizophrenia. He started testing drugs that cause convulsions: first on animals, and then 
on humans. The best results were obtained by experimenting with intravenous injection of 
metrazole (3). In 1937, Ugo Cerletti, a neurologist, while observing the “anesthesia” of pigs in 
the slaughterhouse, realized that an epileptic seizure could be triggered in a different way – by 
conducting electricity through the patient’s body, just as the butchers did to the pigs. After 
many attempts and numerous experiments on animals, in April 1938, in collaboration with 
Luci Bini, the ECT was first used on a human being (4). It was a patient diagnosed with 
schizophrenia and accompanying delusions, hallucinations and confusion, and series of 
electroshocks improved his condition. Throughout the following years, ECT has expanded 
throughout the world and has become one of the ways to treat symptoms, often in problematic 
patients. 
ECT is as a therapeutic method very effective, although the mechanism of action is not fully 
clear. There are many theories (diencephalon massage theory, dissolution and reconstruction 
theory, reconnection theory, etc.) that are still not proven, however we can say with certainty 
that ECT truly changes the function of different neurotransmitter systems: serotonergic, 5-HT 
(increase in postsynaptic 5-HT receptors, changes in postsynaptic regulation of 5-HT release), 
GABA (decreased synthesis and release), endogenous opiates (increase of the activity), 
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noradrenergic, NA (down-regulation postsynaptic β receptors), acetylcholine (down-
regulation of muscarinic receptors) (1).   
We can distinguish two methods of treatment with ECT: according to the position of the 
electrodes (unilateral and bilateral) and according to the performance (native and 
nonconvulsive) (1). Native ECT is outdated, unethical, and is no longer used. The 
nonconvulsive or mitigated ECT i.e. the ECT we know today is not so dramatic (1). It is 
initiated by the administration of thiopental (short-acting barbiturate) and succinylcholine 
(muscle relaxant), which prevents grand-mal seizures in the conduction of electric current 
through the patient’s body and thus spinal or long bone fractures (5). Barbiturates and muscle 
relaxants prevent blood pressure increase and tachycardia, and excessive bronchial secretion 
induced by n. vagus is avoided by atropine (5). Performing an electrical current of 200 to 
1600 mA in the body of the patient per application lasts only 0.1 to 0.5 s, and the therapeutic 
effect requires a current of 70 to 130 V (1). The ECT is applied in cycles of 12-15 
applications, such as intermittent therapy or maintenance therapy (e.g. once a month). 
There are certain diseases and conditions in which it is highly recommended or strictly 
forbidden to implement ECT, such as: implanted cardiac electrostimulation device, 
myocardial infarction, cardiac arrhythmia, unregulated hypertension, abdominal aorta 
aneurysm, cerebral aneurysm, fresh cerebral hemorrhage, elevated intracranial pressure, brain 
tumor, acute respiratory infection (5). 
Indications for which ECT is recommended are depression, schizophrenia, mania, suicidality, 
resistance to therapy. Generally, indications can be categorized into ECT as the first line of 
therapy, second line of therapy and so-called “last-resort” therapy (6). The first line of therapy 
includes cases of febrile catatonia, neuroleptic malignant syndrome (NMS), major depressive 
episode, schizoaffective psychosis, schizophrenia and life-threatening, pharmacologically 
caused adverse effects. The second line of therapy implies failure of depression treatment 
with conservative methods, schizoaffective psychosis, schizophrenia, mania, depression and 
psychotic symptoms of organic etiology. ECT as the “last-resort” therapy involves cases of 
therapeutic resistance and in some areas – obsessive-compulsive syndrome, dyskinesia, Gilles 
de la Tourette syndrome, epilepsy, Parkinson’s disease. Nowadays, in developed countries, 
the most frequent indication for ECT is depression. Other indications are mainly mania and 
schizophrenia (7). Regardless of the indication, it is necessary to obtain an informed consent 
from the patient. If due to the nature of the illness, the patient is unable to give an informed 
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consent (catatonia, stupor, mania, acute paranoid conditions), then it is possible to obtain 
consent from by the law assigned caregivers (6).  
As with other medical procedures, there are some complications and unpleasant side effects 
with ECT as well. The most common are confusion, delirium, temporary headache, muscle 
ache, vomiting, tooth injuries, circulatory collapse, and prolonged convulsions (8). The most 
important are the cognitive side effects that can be divided into postictal disorientation or 
confusion, anterograde amnesia, retrograde amnesia, and cognitive adverse effects not 
connected with memory (9). Postictal confusion does not last long and therefore does not 
represent a significant clinical problem, while the anterograde amnesia may last for a couple 
of weeks or even months, and the retrograde amnesia about autobiographical data may 
potentially be a lasting consequence of the ECT (10). Cognitive side effects usually depend on 
factors such as the application site, the amount of electrical energy the patient will receive, 
and the frequency of the application (11), so that the unwanted effects can be reduced by 
using short or ultrasound stimulation and the right unilateral instead of bilateral application or 
bitemporal convulsion (12). ECT is considered to be a therapy of extremely low morbidity 
and mortality. Fatalities are only 2-4.5 per 100,000 performed procedures, which can be 
compared with the risk of anesthesia during small surgeries (13). Every patient who is about 
to receive ECT must be familiar with the benefits of this therapy and the potential 
consequences.  
The primary purpose of the ECT was to cure or at least to relieve ailments of schizophrenia. 
Thus, ECT was a standard for treating schizophrenia up to 1950s until it was overshadowed 
by more effective antipsychotics (14). Schizophrenia is the most known chronic psychiatric 
disorder affecting approximately 24 million people around the world (15). It is a psychotic 
disorder that disturbs the mind, mood, behavior, and/or personal relationships, leaving 
devastating consequences on the individual and his family (16) and significantly damages the 
person’s functionality and his quality of life, causing various forms of disability. The 
frequency of schizophrenia in the general population is 1%, affecting men and women 
equally. The first psychotic episode usually occurs in late teenage years and early twenties or 
even thirties (16). Men are mostly affected in the early age and women later in life. The 
symptoms of schizophrenia can be divided into positive, negative and cognitive. Positive 
symptoms include hallucinations, most commonly hearing delusions, unorganized thinking, 
and unorganized psychomotor behavior (catatonia) (16). They are the most common in the 
acute phase of the disease and are very recognizable. Negative symptoms are flat affect 
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(difficulty in showing and experiencing feelings), avolition (lack of motivation), social retreat, 
alogia (poverty of speech), anhedonia (inability to experience satisfaction and enjoyment in 
life), and concentration problems (15). These symptoms contribute to patient’s 
inconspicuousness and are in fact the cause of the lack of quality social interaction. Cognitive 
symptoms include disturbances of attention, memory and abstract thinking, which are 
responsible for the dysfunction of a schizophrenic patient in their daily lives (15). Because of 
these symptoms, the patients can not plan their daily lives, their actions are not subject to any 
logic, and cannot logically infer or distinguish essential from irrelevant and have memory, 
attention, concentration, and executive functions. In this division, positive, negative and 
cognitive symptoms may include depressive symptoms (15). They are related to mood of the 
patient and are the main culprit for suicide attempts. 
Schizophrenia can be divided into several clinical types characterized by predominant 
symptoms: a paranoid-hallucinatory type characterized by paranoid delusional ideas, auditory 
hallucinations and hypochondriac delusional ideas, a hebephrenic (disorganized) type 
dominated by depersonalization and derealization phenomena, a catatonic type specific for 
hypo or hyperkinetic phenomena and simplex type – chronic, agonizing, late-recognizable, 
which most often has an unfavorable outcome (15).  
Diagnostic criteria are summarized in two contemporary psychiatric classifications: 
International Classification of Diseases and Related Health Problems, 10
th
 revision (ICD-10) 
(16) and Diagnostic and Statistical Manual of Mental Disorders, 5
th
 edition (DSM 5) (17). 
Although DSM is more commonly used in the Western countries and for research purposes, 
ICD-10 criteria are in our environment officially accepted for diagnosis (15).  
Criteria mentioned by DSM 5 include the presence of two or more characteristic symptoms 
delusional ideas, hallucinations, unorganized speech, catatonia or negative symptoms 
(avolition, desocialization, autism) that persist for most of the time during one month with 
uninterrupted signs of normal functioning during at least 6 months (18). It is of utmost 
importance, besides talking to the patient, to talk to other family members or people close to 
the patient in order to establish the diagnosis. A valid diagnosis should also exclude any other 
primary mood disorder, schizoaffective disorder, intoxication or withdrawal syndrome, or any 
other condition (15). Unfortunately, the time that passes from the onset of the first symptoms 
of schizophrenia till the arrival to the doctor for a treatment is often too long and lasts for 3-5 
years, or longer. The resistance of positive and/or negative symptoms in schizophrenia means 
resistance to psychopharmaceuticals or persistence of symptoms in patients regardless of 
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therapy. Even 40-70% of patients with therapeutic-resistant schizophrenia suffer from 
symptoms despite adequate clozapine therapy (19). In this case, ECT is used as “last-resort” 
therapy. States in schizophrenia that are most frequently treated with ECT are antipsychotic 
therapy resistance, affective symptoms, catatonia, neuroleptic malignant syndrome (NMS). Of 
these, the most successful treatment is the one of catatonia, and then positive symptoms such 
as paranoid delusional ideas and affective symptoms (20).  
Depression is today the most common indication for ECT. The word depression is derived 
from the Latin word deprimere, which means to depress, suppress, press (21). This is a mood 
disorder in which the patient is pervaded by the feeling of sadness, s/he loses any will for the 
activities, even for those that once brought pleasure. Except for these two symptoms, there are 
some others, such as sleep disorders, changes in appetite and weight, hyposexuality, social 
isolation, lack of energy, poor concentration, and psychomotor problems, sense of 
worthlessness and guilt, and suicidality (22).  
It is important to distinguish between a major depressive disorder (MDD), a bipolar disorder 
and a mood disorder caused by some other medical diagnosis (e.g. tumor). It is also important 
to differentiate a major depressive disorder from a major depressive episode (MDE). The 
major depressive disorder is chronic disease characterized by relapses, and the depressive 
episode is when depression occurs for the first time. Depressive episodes vary in intensity 
from mild, moderate, to severe depressive episodes with or without psychotic symptoms, and 
the symptoms should last at least two weeks, every day, almost all day (21). To diagnose a 
new depressive episode or a major depressive disorder, there must be a period of at least 2 
months without depressive symptoms, before a new depressive episode emerges (21). Just as 
with schizophrenia, one of two classifications can be used: ICD-10 or DSM-5. 
In recent years, depression is on the rise. It is believed that by 2020 depression will be the 
second most common place in the world immediately after cardiovascular diseases (21). 
Depression is almost twice as likely in women as in men (2:1), regardless of race, ethnicity or 
socioeconomic status (21).  
Antidepressants, which are widely used today, in as many as 30-40% of patients who take 
them regularly, they are ineffective (22). In such patients, the ECT has been proved as an 
effective “antidepressant”. The percentage of success, i.e. effectiveness of ECT in clinical 
trials on depression is as high as 70-90% (23). 
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Bipolar affective disorder (BAD) is a mood disorder, with characteristic switching between 
depressive, manic and hypomanic episodes. The manic episode of BAD is characterized by an 
elevated, irritable mood in combination with three or more of following symptoms: reduced 
need for sleep (insomnia), grandiosity or excessive self-confidence, fast and hurried speech, 
lack of focus, problematic behavior, a stream of thoughts and ideas, participation in risky 
activities (24). Hypomania is similar to mania, but it’s not psychotic to the point that it creates 
functional problems for the patient that would require hospitalization. In order to diagnose a 
depressive episode, just like for depression, the symptoms must be present for at least 2 
weeks. There is also a mixed episode that has elements of manic and depressive episodes, 
almost every day for a week.  
Bipolar affective disorders can be divided into bipolar disorder I, II, cyclothymic disorder 
(cyclothymia). Bipolar disorder I is defined by a manic episode that lasts for at least seven 
days or manic symptoms that are so serious that a person needs urgent hospitalization and 
depressive episodes that last for at least two weeks. Bipolar disorder II is characterized by 
depressive and hypomanic episodes. Cyclothymia is a characteristic alteration of many 
hypomanic and depressive symptoms over a period of two years, but the symptoms do not 
meet the criteria for diagnosing hypomanic or depressive episodes (25). Depressive symptoms 
are relatively easy to recognize, and the person herself/himself will notice that they are not 
feeling as good as they normally do. The problem arises when a person needs to be convinced 
that his or her manic episodes are not part of normal behavior.  
For diagnosis, we use one of the two standard classifications: ICD-10 or DSM 5. Bipolar 
affective disorder can range from 0.3 to 1.5% of the total adult population, and appear in the 
same ratio in women and men (26). For the first time, they typically occur during adolescence 
up to the early 20s in the form of depressive episodes (27). 
Bipolar disorders are commonly treated with so-called mood stabilizers. In addition, they can 
be treated with typical and atypical antipsychotics, but also with ECT (6). Even though, ECT 
has proved its superiority over lithium – the most well-known mood stabilizer (28) through 
many research, the ECT will be seen as the first line treatment only in the case of psychotic 
mania (29). 
Suicidality is the next significant indication for treatment with ECT. The world suicide is a 
compilation of two Latin words: sui and occidere what in literal translation means to kill 
yourself (30). Silverman et al. classify suicidal behavior as a suicide threat, a suicide plan, 
self-injury, suicide attempt, suicide, indefinite conduct related to suicide (30). Psychiatric 
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disorders that carry 10-15% higher risk of suicide than other disorders and psychiatric 
diagnoses are BAD, alcoholism and depression, followed by schizophrenia, personality 
disorders and other addictions (31). The suicide rate in bipolar disorders is 164/100 000 
persons per year (32) and in schizophrenic patients 579/100 000 people per year (33). 
According to Mayo Clinic survey, 2-9% of people diagnosed with depression during their life 
will commit suicide, that is, they will successfully take away their life (34). Voracek and 
Lobil found that suicidal behavior is inherited in 30-55% of cases and is very likely 
independent of psychiatric disorders (35). 
Five of the most common forms of suicidality determined by the dimensions of the disease 
are: psychotic (as a result of frenzy and hallucination), depressive (as a result of feeling of 
hopelessness), disorganized (disorganized functionality, confusion without conscious desire 
for suicide), alienation (associated with lack of appropriate social support as a result of 
withdrawal from social life), and ultimately reactive suicidality (as a reaction to stressful 
events, family conflicts) (30). 
According to the World Health Organization (WHO), about 800 000 people commit suicide 
each year, which would mean roughly one life is lost every 40 seconds (36). Even more 
alarming is the fact that suicide is the second leading cause of death in people aged 15 to 29 
years. Suicide, which appears as a symptom of mental illness, is treated conservatively with 
antidepressants in combination with antipsychotics, but as well with ECT and 
psychotherapeutic methods. Suicidality as an indication for ECT may be acute suicidality or 
chronic continuous suicidality which does not respond to conventional methods of treatment. 
Neuroleptic malignant syndrome (NMS) is life-threatening and emergency condition caused 
by psychopharmaceutical drugs. This potentially lethal complication is recognizable by 
hypothermia muscular rigidity, changed consciousness state, and autonomic nervous system 
dysfunction (37). The muscle rigidity, that is, the heat that the muscle produces is such state 
could explain hyperthermia, which can lead to dehydration and electrolyte disbalance, putting 
the patient at increased risk for infection (38). Laboratory findings, such as elevated serum 
creatine phosphokinase (CPK), could also be explained by the rigidity of the muscles and 
their self-destruction, which leads to myoglobinuria and acute kidney failure (38). Other 
laboratory findings are leukocytosis and elevated liver enzymes (39). The frequency or 
neuroleptic malignant syndrome in patients who are treated with antipsychotics of the first 
generation, selective serotonin reuptake inhibitors (SSRI), monoamine oxidase inhibitors 
(MAOIs) and tricyclic antidepressants (TCA) was estimated to be 0.5% (39). Frequency is 
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higher in young men who are malnourished and dehydrated, have Parkinson’s disease or 
parenterally receive high doses of neuroleptics over a short period of time (40). Some papers 
confirm that the risk for NMS is higher in patients received ECT (41). It is unknown what 
exactly causes NMS in some people, and in others, it does not. It is thought that NMS is 
caused by blockade of hypothalamic and striatal dopamine receptors, as they also act on 
thermoregulation and muscular spasm (39). Once a patient is diagnosed with NMS, 
antipsychotics are immediately discontinued and bromocriptine is administered, and 
sometimes the ECT is used. The temperature, just like the electrolytes, is tried to be withheld 
within the normal limits (39). It has also been confirmed that there is no certain type of 
neuroleptic that has greater or lesser potential for NMS, however, it is generally considered 
that typical antipsychotics have a greater risk (38). 
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HYPOTHESIS 
1) Indications for ECT in the treatment of major mental disorders, compared to 
traditional indications, have been extended to suicidality, catatonic state, MNS, 
schizophrenia, depression, and therapeutic resistance in mental disturbances. 
2) There are sex and age differences between patients treated with ECT in regard to the 
diagnosis of mental illness and the indication for the ECT.  
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OBJECTIVES 
The aim of the study is to examine the general and specific features of patients treated with 
ECT in the period from 2010 till 2017 at the Clinic for Psychiatry, Clinical Hospital Center 
Zagreb.  
General demographic characteristics will determine the sex and age distribution of the patient, 
as well as other characteristics related to work, education, family and social status and 
heredity. 
The frequency of mental diseases diagnoses in patients treated with ECT, type of early 
therapy attempts, suicidal attempts, psychoactive substance abuse and the number of 
psychiatric hospitalizations to date will be investigated. The age when the first psychiatric 
treatment begins and the age of the first application of the ECT will be investigated. 
Indications for the application of the ECT will be analyzed in 6 specific groups of indications: 
suicidality, therapeutic resistance to schizophrenia with positive symptoms and schizophrenia 
with negative symptoms, therapeutic resistance to all diagnoses, catatonia, and NMS. 
  
The number of applications, side effects, and termination of therapy will be analyzed and 
outcome in the form of re-hospitalization of patients within the first year after the ECT. 
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METHODS 
This study is a retrospective analysis of the medical documentation of the patients treated with ECT 
from 2009 till 2017 at the Clinic for Psychiatry at the Clinical Hospital Center Zagreb. In this period 
213 patients have been treated with ECT. All patients had a history of previous psychiatric treatment, 
as well as recorded earlier multiple-course therapeutic trials using conventional treatment methods. 
Patients underwent standard clinical protocol for ECT which includes hospitalization. The protocol 
also includes psychiatric evaluation, diagnosis and confirmation of ECT indication, general laboratory 
findings, EEG, CT of the brain, internal medicine specialist, and anesthesiologist check-up, and 
exclusion of contraindications for the electroconvulsive therapy. Psychiatric diagnoses were based on 
ICD-10 (16).   
Patients are referred to ECT by the department psychiatrist, psychiatrist from another institution in the 
city, region or even state. All patients had to sign an informed consent for the ECT, and the Ethics 
Committee of Clinical Hospital Center Zagreb had to approve every single case in order for the 
therapy to be performed. A bitemporal ECT was used, and patients were situated in the intensive care 
unit during the ECT treatment. The ECT was performed 3 times a week, and during the applications, 
the patients received their usual or customized pharmacological therapy unhindered. The ECT is being 
performed as a medical intervention in short-term anesthesia by a team of a psychiatrist, an 
anesthesiologist, an anesthesiologist technician, a psychiatric medical technician and nursing staff. 
Premedication was atropine, 0.5 mg subcutaneously, 30 minutes before ECT, with the aim of 
preventing increased salivation and decreased heart rate during stimulation. Anesthetized intravenous 
medications that relieve the muscles and cause short-term deep sleep (most often propofol and 
lysthenone in dilution according to anesthesiologist recommendation), with vital signs monitoring. 
The ECT is applied by a psychiatrist for a few seconds (2-5 seconds) so that the electrode of the 
apparatus touches the temple area, both sides. The whole procedure, including anesthesia induction 
and awakening, lasts 5 to 10 minutes. 
All data on hospitalization, ECT and the patients themselves were obtained from the patients’ history 
in its written and/or digital form. They were analyzed according to the age, sex, number of previous 
hospitalizations, previous therapies, diagnosis, leading diagnosis, number of ECT applications and 
outcome. Statistical analyses were carried out by the SPSS computer software (19.0 version for 
Windows). The methods used for descriptive statistics are frequency methods, percentages, arithmetic 
mean, standard deviation, minimum and maximum value. Interferential statistical analyses included a 
chi-square test, a t-test for independent samples and a one-way variance analysis (ANOVA) with the 
associated post hoc Scheffe test. The level of statistical significance was set at 5%, p = 0.05.  
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RESULTS 
Table 1. Sociodemographic features of the sample  
 
 Frequency Percentage 
Valid 
Percentage 
Cumulative 
Percentage 
Sex 
Men 105 49.3 49.3 49.3 
Women 108 50.7 50.7 100.0 
Education 
Primary school 19 8.9 8.9 8.9 
Secondary school 148 69.5 69.5 78.4 
Higher education 46 21.6 21.6 100.0 
Employment 
status 
Missing 1 .5 .5 .5 
Unemployed 95 44.6 44.6 45.1 
Employed 54 25.4 25.4 70.4 
Retired 48 22.5 22.5 93.0 
Educating 15 7.0 7.0 100.0 
Marital 
status 
Single 112 52.6 52.6 52.6 
Married 92 43.2 43.2 95.8 
Divorced/Widowed 9 4.2 4.2 100.0 
Parenthood 
None 120 56.3 56.6 56.6 
With kids 92 43.2 43.4 100.0 
In total 212 99.5 100.0  
Missing 1 .5   
Heredity 
None 66 31.0 31.0 31.0 
Mother 23 10.8 10.8 41.8 
Father 24 11.3 11.3 53.1 
Brother/Sister 8 3.8 3.8 56.8 
Other cousins 40 18.8 18.8 75.6 
Unknown 52 24.4 24.4 100.0 
In total 213 100.0 100.0  
 
Out of 213 hospitalized psychiatric patients, there was approximately the same number of women (N = 
108) and men (N = 105), of which most of them finished at least secondary school (N = 148). The 
majority of them were either unemployed (N = 95) or retired (N = 48), in total 143 patients without a 
job. Considering marital status 112 patients were single, 9 divorced and 92 married, while 43.2% has 
children. Heredity is positive in 44.7% of the patients.  
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Table 2. Analysis of psychiatric treatment 
 
 
Diagnoses 
 Frequency Percentage 
Valid 
Percentage 
Cumulative 
Percentage 
Schizophrenia 120 56.3 56.3 56.3 
Delusional 
disorder 
3 1.4 1.4 57.7 
Acute 
psychotic 
episode 
4 1.9 1.9 59.6 
Shizoaffective 32 15.0 15.0 74.6 
Non-organic 
psychosis 
1 .5 .5 75.1 
BAD 25 11.7 11.7 86.9 
Depression 2 .9 .9 87.8 
Recurrent 
depression 
26 12.2 12.2 100.0 
Clozapine 
Yes 110 51.6 51.6 51.6 
No 103 48.4 48.4 100.0 
In total 213 100.0 100.0  
Suicide attempt 
No 171 80.3 80.3 80.3 
One attempt 24 11.3 11.3 91.5 
More attempts 18 8.5 8.5 100.0 
Rehospitalization after 
ECT 
No 164 77.0 77.0 77.0 
Yes 49 23.0 23.0 100.0 
In total 213 100.0 100.0  
 
 
The average number of hospitalizations before ECT was 4.7 (sd = 4.65143, range 0-24 times). The 
average age of the first psychiatric treatment was 29.3 years (sd = 12.15233, range 11-66 years). The 
average age of the first treatment with ECT was 39.1 (sd = 12.942, range 18-77 years). Before the 
ECT all patients were treated with combined pharmacotherapy, most often antipsychotics (100%), 
antidepressants (39%), mood stabilizers (35%) and anxiolytics (92%). 
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Table 3. Analysis of ECT features 
Average number of ECT applications was 9.5 (sd = 3.54962, range 1-18) in 213 patients. 
Indications for 
ECT 
 Frequency Percentage 
Valid 
Percentage 
Cumulative 
Percentage 
Suicidality 24 11.3 11.3 11.3 
Resistance to 
therapy 
51 23.9 23.9 35.2 
Therapy resistant 
schizophrenia with 
positive symptoms 
94 44.1 44.1 79.3 
Therapy resistant 
schizophrenia with 
negative symptoms 
25 11.7 11.7 91.1 
NMS 4 1.9 1.9 93.0 
Catatonia 15 7.0 7.0 100.0 
Disrupting 
ECT 
 
No 27 12.7 12.7 12.7 
Yes 186 87.3 87.3 100.0 
ECT side 
effects 
 
No 198 93.0 93.0 93.0 
Somnolence 11 5.2 5.2 98.1 
Restlesness 1 .5 .5 98.6 
Cognitive s.e. 3 1.4 1.4 100.0 
In total 213 100.0 100.0  
 
Table 4. Comparison according to age and sex 
Women and men differ considerably (according to the t-test) considering the age of 
the first ECT application: women are older than men.  
 Sex N Mean Std. Deviation Std. Error Mean 
Age of ECT 
application 
Male 105 35.3558 12.05160 1.18176 
Female 108 42.7736 12.78413 1.24170 
 
 95% Confidence Interval od the Difference 
 T Df Sig. (2-tailed) 
Age of 
ECT app. 
Equal variances assumed -4.325 208 .000 
Equal variances not assumed -4.327 207.671 .000 
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Table 5. Comparison according to sex and prevalence of individual psychiatric diagnoses 
Women and men statistically differ significantly according to the prevalence of individual diagnoses 
(based on the chi-square test): among men, there is a significantly higher number of those diagnosed 
with schizophrenia, while among women there are more depression and schizoaffective disorders 
diagnosed. Women and men don’t differ when it comes to diagnosis of BAD. 
sex * diagnosis Cross tabulation 
 Diagnosis In total 
Schizophrenia SAD BAD Depression 
Sex 
Male 
Count 76 10 12 7 105 
% within the 
gender 
72.4% 9.5% 11.4% 6.7% 100.0% 
% of men 
diagnosed with 
59.4% 31.3% 48.0% 25.0% 49.3% 
% out of total 35.7% 4.7% 5.6% 3.3% 49.3% 
Female 
Count 52 22 13 21 108 
% within the 
gender 
48.1% 20.4% 12.0% 19.4% 100.0% 
% of women 
diagnosed with 
40.6% 68.8% 52.0% 75.0% 50.7% 
% out of total 24.4% 10.3% 6.1% 9.9% 50.7% 
In total 
Count 128 32 25 28 213 
% within the 
gender 
60.1% 15.0% 11.7% 13.1% 100.0% 
% of diagnosed 
patients 
100.0% 100.0% 100.0% 100.0% 100.0% 
% out of total 60.1% 15.0% 11.7% 13.1% 100.0% 
 
Chi-Square Tests 
 Value df Asymp. Sig. (2-sided) 
Pearson Chi-Square 16.001a 3 .001 
Likelihood Ratio 16.462 3 .001 
Linear-by-Linear Association 11.258 1 .001 
N of Valid Cases 213   
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 12.32. 
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Table 6. Comparison according to sex and the indication for ECT 
1 = therapy resistant mood disorder; 2 = therapy resistant schizophrenia with positive symptoms; 3 = 
therapy resistant schizophrenia with negative symptoms 
indication2 * sex Cross tabulation 
   Sex In total 
   Male Female 
 
Indication 
1 
Count 19 32 51 
% within the 
indications 
37.3% 62.7% 100.0% 
% within the 
gender 
23.2% 36.4% 30.0% 
% out of total 11.2% 18.8% 30.0% 
2 
Count 54 40 94 
% within the 
indications 
57.4% 42.6% 100.0% 
% within the 
gender 
65.9% 45.5% 55.3% 
% out of total 31.8% 23.5% 55.3% 
3 
Count 9 16 25 
% within the 
indications 
36.0% 64.0% 100.0% 
% within the 
gender 
11.0% 18.2% 14.7% 
% out of total 5.3% 9.4% 14.7% 
In total 
Count 82 88 170 
% within the 
indications 
48.2% 51.8% 100.0% 
% within the 
gender 
100.0% 100.0% 100.0% 
% out of total 48.2% 51.8% 100.0% 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Pearson Chi-Square 7.156
a 2 .028 
Likelihood Ratio 7.218 2 .027 
Linear-by-Linear 
Association 
.357 1 .550 
N of Valid Cases 170   
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Indications differ significantly according to gender: in groups of indications of therapy-resistant mood 
disorders and therapy-resistant schizophrenia with negative symptoms are more women, while in the 
group of indications of therapy-resistant schizophrenia with positive symptoms more men. 
 
Table 7. Age and indication for ECT 
1 = therapy resistant mood disorder; 2 = therapy resistant schizophrenia with positive symptoms; 3 = 
therapy resistant schizophrenia with negative symptoms 
Table. Comparison according to the age and indication for ECT 
 
 N Mean Std. 
Deviation 
Std. 
Error 
95% Confidence 
Interval for Mean 
Minimum Maksimum 
AGE 
ECT 
Lower 
Bound 
Upper 
Bound 
  
1 49 48.1837 12.48778 1.78397 44.5968 51.7706 18.00 77.00 
2 93 33.6667 10.43961 1.08254 31.5167 35.8167 18.00 64.00 
3 25 41.8800 13.16979 2.63396 36.4438 47.3162 20.00 64.00 
In total 167 39.1557 13.13873 1.01671 37.1483 41.1630 18.00 77.00 
 
 
Table 8. ANOVA test 
AGE ECT Sum od Squares df Mean Square F Sig. 
Between Groups 6981.298 2 3490.649 26.412 .000 
Within Groups 21674.654 164 132.163   
In total 28655.952 166    
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Table 9. Differences between indications according to age 
1 = therapy resistant mood disorder; 2 = therapy resistant schizophrenia with positive symptoms; 3 = 
therapy resistant schizophrenia with negative symptoms 
 
(I) Indication (J) Indication Mean Difference (I-
J) 
Std. 
Error 
Sig. 95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
1 2 14.51701
* 2.02936 .000 9.5039 19.5301 
3 6.30367 2.82554 .086 -.6762 13.2835 
2 1 -14.51701
* 2.02936 .000 -19.5301 -9.5039 
3 -8.21333
* 2.58990 .008 -14.6111 -1.8156 
3 1 -6.30367 2.82554 .086 -13.2835 .6762 
2 8.21333
* 2.58990 .008 1.8156 14.6111 
*. Statistical significance at 0.05 level. 
 
According to variance analysis (ANOVA), significant differences were found between three age-
related indications: the post-hoc Scheffe test shows that indications 1 and 2 differ significantly 
(patients with mood disorders are significantly older than patients with schizophrenia with positive 
symptoms), and indications 2 and 3 (patients with schizophrenia with negative symptoms are 
significantly older than patients with schizophrenia with positive symptoms) (Table 7 and 8). 
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DISCUSSION  
In the period from January 1
st
, 2010 until March 1
st
, 2017 in the Department of Psychiatry of 
the Clinical Hospital Center Zagreb there were 213 patients of both sexes (m = 105, w = 108) 
who received ECT. All patients were hospitalized during the therapy. The indication for the 
treatment with the ECT was set up by a competent psychiatrist. Each patient signed a special 
informed consent for the treatment with the ECT and then received the approval of the 
hospital Ethics Committee. The most common indication for the treatment with the ECT was 
therapy resistance and considering diagnostic categories, schizophrenia and mood disorders. 
 
Analysis of demographic characteristics and heredity of patients on ECT 
The average age of the patients in the study was 39 years, with male patients being 
considerably younger than female patients on ECT. Many studies find the significantly earlier 
age of the first ECT application in the age group of 20-29 years, which differs from the 
average age of our examined group (42, 43). However, in American Centers, the average age 
of patients getting the ECT is older (44). The ECT in the treatment of psychiatric disorders is 
considered equally effective in all age groups (45). 
In our examined group there was an almost equal number of female and male patients who 
received the ECT. Some studies find a higher incidence of female patients on the ECT (46, 
47). 
Most patients have a secondary school education (N = 148), they are not working 
(unemployed = 95, retired = 48), and approximately every other has not married (N = 112) 
and has no children (N = 120). The first episodes of all major psychiatric disorders 
(psychosis, depression, BAD) often occur in adolescence and early adulthood and have an 
adverse effect on schooling, school, and academic success, normal psychological 
development, social and emotional ties, employment and self-reliance (1). The clinical 
significance and intensity of mental illness and the failure of conventional therapeutic 
methods that later result in treatment with ECT may also be the reason for the inability to set 
up a family and to hire or retire. Heredity is positive in 44.4% of patients, which is higher than 
expected in the general population. According to previous research, the expected heredity for 
schizophrenia is 6-18%, for depression and BAD is higher. A higher percentage of heredity in 
a group of patients receiving ECT can be interpreted by the increased clinical intensity and/or 
disability caused by mental disorder. The anticipatory theory of inheritance of schizophrenia 
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presupposes the early occurrence of diseases and severe forms of disease in the next vertical 
generation (1). In ¼ of patients, there is no data on heredity, which does not mean the absence 
of heredity, so the percentage of heredity is probably even higher. 
The mean age of the first psychiatric treatment (M = 29.3) is, as expected, earlier than the age 
of the first received ECT (M = 39.1), and the wide range is visible in both cases. The 
youngest patient that received ECT application was 18 years old and the oldest was 77 years 
of age. The average length of psychiatric treatment is indicative before deciding to treat with 
ECT. On average, it passes 10 years from the first psychiatric treatment to the first application 
of ECT, indicating a certain therapeutic inertia, a physician’s inability, and prejudices towards 
the treatment with ECT by patients, families, and specialists as well. Although there is no 
information on Duration of untreated psychosis (DUP) before the first psychiatric treatment, 
the average age of the first treatment is 29 years, which indicates late recognition of the 
disease and consequently late treatment. Late recognition and late treatment of the psychiatric 
illness, especially psychosis, is connected with unfavourable outcome of the treatment, 
decreased quality of life, and probably with progression of psychiatric disease with 
development of the clinical picture, dysfunctionality and disability of the patient, as well as 
unfavourable effect on the biology of the brain (1). The earlier treatment is connected with the 
better therapeutic response, which decreases the risk of therapeutic resistance and treatment 
failure, and in that way, we avoid invasive treatments, such as ECT. The average number of 
psychiatric hospitalizations prior to the ECT therapy is 4, with the maximum being 24. The 
phenomenon of frequent psychiatric hospitalizations (revolving door) is connected with low 
compliance, avoidance to take the prescribed therapy, unfavorable social and familial status 
and with less intensive symptoms. Therapeutic resistance could be the factor responsible for 
frequent psychiatric hospitalizations. For the patients in this research, we confirmed the 
failure of conventional forms of treatment. 
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Analysis of diagnoses of psychiatric patients on ECT  
Patients who were treated with ECT, most commonly had following diagnoses: schizophrenia 
and psychoses (N = 160), depression (N = 28) and BAD (N = 25). In this sample, there is no 
other diagnostic category which, according to the literature could have gained benefits from 
ECT (e.g. dementia, PTSD, obsessive-compulsive disorders etc.), and this designates the strict 
frame of indications seen in clinical praxis. This proves that praxis in Croatia is very similar 
to the one in Hungary, Czech Republic, Estonia, Lithuania, where schizophrenia is the main 
diagnosis that is treated with ECT, whereas, for Poland, Slovakia, Bulgaria, Ukraine, and 
Serbia the main diagnoses are affective disorders (48).  
Earlier suicide attempts are noted in 18% of patients, and suicidality as an indication for ECT 
was noticed in 11% of patients. Differences exist due to suicidality being transdiagnostic and 
dynamic psychological phenomenon; it is rarely acute indication for ECT. Suicidality, as an 
indication for ECT, is observed as continuity of suicidal ideas and compulsions, with or 
without attempts, and of a chronic character. No patients were treated with ECT because of 
acute suicidality or the first episode of suicidality. The frequency of suicidality in this sample 
is in correlation with expected frequency of suicidality, considering the diagnoses of 
schizophrenia, depression and BAD. 
 
Analysis of treatment before ECT  
All the patients were treated with combined pharmacotherapy in many therapeutic attempts 
before ECT. Most commonly these were antipsychotics (100%), anxiolytics (92%), 
antidepressants (39%), and mood stabilizers (35%). This was also a requirement to define 
therapeutic resistance and approval from the Ethics Committee. Half of the patients were 
already treated with clozapine – antipsychotics reserved for resistant psychosis and 
suicidality. Therefore, we can consider ECT a “last-resort” therapy for the therapeutic 
resistant states (49).  
 
Analysis of indications for ECT treatment 
Diagnosis of psychiatric disease per se is not an indication for ECT treatment. Indications for 
applications of ECT are determined individually for each patient. Most commonly it depends 
on the success or failure of the treatment and the endurance of the disease symptoms or the 
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existence of risk states such as suicidality or aggressiveness, catatonia, and NMS. In this 
study, we investigated specific indications for referral of patients to treatment with ECT, 
relative to the primary diagnosis of mental illness.  
For the period of 7 years, the most common indication for treatment with ECT was the 
evaluation of therapeutic resistance, meaning lack of therapeutic response to conventional 
treatment methods, mainly combined pharmacotherapy (N = 79.7%). Traditionally, primary 
indications for ECT suicide and catatonia, and NMS are significantly less represented. If a 
strict indicative framework of primary indications was used to determine indications 
(suicidality and catatonia) only 39 patients would receive ECT therapy, as opposed to 213 
patients.  
Studies show significant differences in indications for ECT in other clinical centers, 
Generally, in developed countries, primary ECT indications are mood disorders, i.e. 
depression (50,51). In Asian countries, common indications are schizophrenia and psychosis 
(52). In one Indian study from 2011, the most common indications for ECT in schizophrenia 
patients were augmentation of pharmacotherapy, followed by therapeutic response urgency 
and treatment resistance, which is only partly consistent with findings of this study where 
treatment resistance was the first indication (53). The results that were the most similar to the 
results of this study are the ones from Hungarian practice, where through surveys they 
concluded that psychiatrists most frequently recommended ECT for antipsychotic and 
antidepressant-resistant patients (54). This study shows a higher incidence of treatment with 
ECT due to therapeutic resistance, while treatment of primary indications, suicidality, and 
catatonia is less represented in this sample. According to literature, the pattern of ECT 
frequency is somewhat higher on the side of mood disorders, i.e. depression, relative to 
schizophrenia and psychosis, as opposed to this sample having a reverse indicative pattern. 
With regard to more than thirty years of experience with ECT at the Psychiatric Clinic, this 
trend indicates the probable effect of clinical experience and practice in treating primarily 
therapeutic resistance in schizophrenia, and then in other indications, while suicide and 
catatonia are less represented (55). A small number of NMS (4 patients) is probably due to a 
greater prescription of atypical antipsychotics in modern psychiatry and the frequency of 
treatment with clozapine.    
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Indications for ECT with regard to age and sex of the patient 
The trend of referral of patients to therapy at the Psychiatric Clinic is significantly different in 
relation to the gender of the patient relative to the indications. Male patients getting treated 
with ECT are more likely to have the diagnosis of schizophrenia than female patients. Women 
referred to ECT more often suffer from depression and schizo-affective disorders. For the 
diagnosis of BAD, there are no differences between sexes.    
This corresponds to the previous findings that in Western countries majority ECT treated are 
older women with depression on contrary to younger men with schizophrenia in Asian 
countries (56). However, even in Asia, there are exceptions. In Japan, Hong Kong, Pakistan 
and Saudi Arabia, female sex and depression predominance were also observed, except for the 
younger age (56). In this study, women who have been referred to the ECT at the same time, 
apart from the diagnosis, are also different at age – they are older than male patients receiving 
ECT. This trend suggests a longer waiting period to indicate the treatment for ECT in women, 
which can be explained by the gender differences in the course and outcome of mental illness. 
Sexual differences in mental illness are related to differences in bio-psycho-social changes – 
in women, psychoses occur at a later age, effectively more adequate, they use their social, 
working and family potentials better, partly because of a different social pattern of 
relationships with women in the community. Hormonal differences also have an effect on e.g. 
behavior, so in men, aggressive behavior that is in conjunction with productive symptoms 
becomes a significant risk to the environment. It is generally considered that female sex has a 
better treatment outcome than male in schizophrenia. Although women are more likely to 
suffer from depression, men (probably depressed) are more likely to commit suicide, again 
proving sexual differences in mood disorders and suicidality. Swedish study proved that 
among severely depressed inpatients that received ECT (38%), the proportion treated with 
ECT was higher among women (1105/2771; 40%) than men (661/1940; 34%) (56). The other 
studies also point to a higher proportion of women on ECT then men (57), whereas, in this 
study, the number of males and females treated with ECT is almost the same (women = 108, 
men = 105). It seems that Croatia did not completely follow the shift in Western world 
practice and the increasing use of ECT among women found both in USA and Australia (56). 
This study shows significant age-diagnostic differences in the patient’s group: on ECT 
therapy, younger patients have more resistant, predominantly susceptible symptoms of 
schizophrenia, and older patients are more often suffering from mood disorders and 
schizophrenia with negative symptoms. Considering the age issue, this study corresponds with 
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findings in western countries (Australia, New Zealand, USA, Europe), where the median age 
of patient receiving ECT was above middle age (56).  
In this research there are differences in gender with regard to indications for ECT: male 
patients are more likely to have a dominant positive picture of schizophrenia, and female 
schizophrenia with negative symptoms and mood disorders – depression and BAD. 
Differences in sex are also manifested by the indication for ECT. Schizophrenia with positive 
symptoms, resistant to pharmacotherapeutic treatment attempts is more frequently treated and 
at the earlier age by ECT in men. This could be explained by the need for a better control of 
positive symptoms (hostility, delusions – paranoia, hallucinations, disorganized behavior, and 
thinking, etc.). In women, the development of the disease takes a longer time, and 
schizophrenia with negative symptoms is somewhat calmer, however not less serious because 
it leads to significant dysfunctionality (decline in volition, reduction in affect, withdrawal, 
avoidance of daily activities and social contact, etc.). BAD resistant to therapy is most 
common indication due to the mixed clinical picture, fast-cycling form and psychotic intensity 
of mania and depression. Other studies show mixed results as well, in regards to the relation 
between sex and indication for ECT, and more frequent indication for women are affective 
disorders (52).  
 
Number of ECT applications and side effects  
On average, patients received 9 ECT applications, ranging from 1 to 18 applications. The 
anticipated number of applications in this treatment method ranges from 12 to 15, and the 
number of applications with minimal clinical effect is 6. A lower number of applications 
could imply side effects in older patients or inefficiency estimates. In 12% of patients, the 
therapy was discontinued and 7% had side effects (confusion, forgetfulness, etc.). In general, 
side effects of ECT are considered rare and of a transient character, and most commonly 
described are acute cognitive disturbances associated with effects of anesthesia (58). No 
serious and persistent side effects of treatment have been reported in this study. This is 
consistent with the overall worldwide experience where the report of side effects, adverse 
events, and the mortality rate is sparse (56). 
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Outcome of ECT 
The effect of ECT was assessed by analyzing the frequency or re-hospitalization of patients 
within a year (59). Within a year after ECT, 23% of the patients were re-hospitalized, and 
there was no significant difference in relation to the three different indications. Indications for 
re-hospitalization may be numerous, ranging from clinical deterioration to adverse 
socioeconomic and family circumstances and relationships in which patient lives. It can be 
said that in 2/3 patients the therapy with ECT has sufficiently calmed the symptoms of mental 
illness, which made it possible to continue the outpatient treatment of the patient for the 
patient to return to his community and improve his quality of life. The best therapy is 
combined therapy, and it has already been proven that reduction in the re-hospitalization rate 
in ECT group is more pronounced among those treated with clozapine or a medium-high 
average daily dose of antipsychotics (60). The goal of psychiatric treatment is to treat out-of-
hospital patients in outpatient, outpatient or community settings, enabling better rehabilitation 
of patients in their family and community. 
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CONCLUSIONS 
Therapeutic resistance gains increasing significance as an indication for the treatment with 
ECT, next to primary indications: suicidality, catatonia, neuroleptic malignant syndrome. 
ECT is becoming more commonly used for therapeutic resistance to conventional treatment 
methods in schizophrenia and mood disorders. Apart from differences in the area of relevance 
for the diagnosis of mental illness, referral of patients to ECT may vary according to age, sex, 
and features that dominate the clinical picture of schizophrenia (positive or negative 
symptoms), and it also depends on clinical praxis and experience of the centers that provide 
ECT as a therapy. The best results in treating therapy resistance are expected in combined 
treatment, pharmacotherapy with ECT. Research on the application of ECT as a treatment for 
mental illnesses will provide a better understanding, enable targeted and timely set 
indications, and it will neutralize controversies associated with this treatment method. 
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